{"protocolSection":{"identificationModule":{"nctId":"NCT06471218","orgStudyIdInfo":{"id":"SHR-1918-203"},"organization":{"fullName":"Beijing Suncadia Pharmaceuticals Co., Ltd","class":"INDUSTRY"},"briefTitle":"Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia","officialTitle":"Evaluation of the Efficacy and Safety of Multiple Subcutaneous Injections of SHR-1918 in Patients With Hyperlipidemia in Poor Control: a Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trials"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-06","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2025-04","type":"ESTIMATED"},"completionDateStruct":{"date":"2025-06","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-18","studyFirstSubmitQcDate":"2024-06-18","studyFirstPostDateStruct":{"date":"2024-06-24","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-06-18","lastUpdatePostDateStruct":{"date":"2024-06-24","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Beijing Suncadia Pharmaceuticals Co., Ltd","class":"INDUSTRY"}},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"Evaluation of the efficacy and safety of multiple subcutaneous injections of SHR-1918 in patients with hyperlipidemia in poor control: a multicenter, randomized, double-blind, placebo-controlled phase II clinical trials"},"conditionsModule":{"conditions":["Hyperlipidemia"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":42,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Treatment A:SHR-1918/SHR-1918 Placebo","type":"EXPERIMENTAL","interventionNames":["Drug: SHR-1918; SHR-1918 Placebo"]},{"label":"Treatment B:SHR-1918/SHR-1918 Placebo","type":"EXPERIMENTAL","interventionNames":["Drug: SHR-1918; SHR-1918 Placebo"]}],"interventions":[{"type":"DRUG","name":"SHR-1918; SHR-1918 Placebo","description":"SHR-1918/SHR-1918 Placebo,two administration","armGroupLabels":["Treatment A:SHR-1918/SHR-1918 Placebo","Treatment B:SHR-1918/SHR-1918 Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percent change in calculated LDL-C from baseline to week 24","timeFrame":"from baseline to week 24"}],"secondaryOutcomes":[{"measure":"Percent change in calculated TG from baseline to week 24","timeFrame":"from baseline to week 24"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. On the day of signing the informed consent form, the age must be ≥ 18 years old and ≤ 75 years old, both men and women are eligible;\n2. Screen spatiotemporal abdominal LDL-C for ASCVD risk assessment, meeting the following conditions:\n3. TG≤5.6mmol/L；\n\nExclusion Criteria:\n\n1. (1) Alanine aminotransferase (ALT), aspartate aminotransferase (AST), or gamma glutamyltransferase (GGT) exceeding 3 times the ULN, or total bilirubin exceeding 2 times the ULN;\n2. (2) Human immunodeficiency virus antibody (HIV Ab), hepatitis C virus antibody (HCV Ab), any of the above test results are positive; Hepatitis B virus surface antigen (HBsAg) positive and HBV-DNA ≥ 1000 copies/ml (or ≥ 200IU/ml, if the lower limit of the detection value is higher than 1000 copies/ml or 200IU/ml, HBV-DNA ≥ the lower limit of the detection value);\n3. (3) Creatine kinase (CK) exceeds 3 times the upper limit of normal value (ULN);\n4. (4) Thyroid stimulating hormone (TSH) is below the lower limit of normal (LLN) or exceeds 1.5 times the upper limit of normal (ULN);\n5. (5) Glomerular filtration rate (eGFR)\\<30 ml/min/1.73m2 (calculated using the MDRD formula, eGFR (mL/min/1.73m2)=175 x (serum creatinine/88.4) -1.234 x age -0.179 x (0.79 females), where serum creatinine units are μ mol/L);","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Meng Sun","role":"CONTACT","phone":"+86 18036618718","email":"meng.sun@hengrui.com"},{"name":"Chanjuan Deng","role":"CONTACT","phone":"+86 18672104055","email":"chanjuan.deng@hengrui.com"}],"locations":[{"facility":"Meizhou People's Hospital","city":"Meizhou","state":"Guangdong","zip":"514031","country":"China","contacts":[{"name":"Zhixiong Zhong","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":24.2886,"lon":116.11767}}]},"ipdSharingStatementModule":{"ipdSharing":"UNDECIDED"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"meshes":[{"id":"D000006949","term":"Hyperlipidemias"},{"id":"D000006951","term":"Hyperlipoproteinemias"}],"ancestors":[{"id":"D000050171","term":"Dyslipidemias"},{"id":"D000052439","term":"Lipid Metabolism Disorders"},{"id":"D000008659","term":"Metabolic Diseases"}],"browseLeaves":[{"id":"M10000","name":"Hyperlipidemias","asFound":"Hyperlipidemia","relevance":"HIGH"},{"id":"M10002","name":"Hyperlipoproteinemias","asFound":"Hyperlipidemia","relevance":"HIGH"},{"id":"M26181","name":"Dyslipidemias","relevance":"LOW"},{"id":"M11639","name":"Metabolic Diseases","relevance":"LOW"},{"id":"M27029","name":"Lipid Metabolism Disorders","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC18","name":"Nutritional and Metabolic Diseases"},{"abbrev":"All","name":"All Conditions"}]}},"hasResults":false}